Castle Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Castle Biosciences
CSTL Stock  USD 32.26  0.39  1.22%   
Castle Biosciences financial statements provide useful quarterly and yearly information to potential Castle Biosciences investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Castle Biosciences financial statements helps investors assess Castle Biosciences' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Castle Biosciences' valuation are summarized below:
Gross Profit
105 M
Profit Margin
(0.01)
Market Capitalization
884 M
Enterprise Value Revenue
2.2583
Revenue
287.6 M
There are over one hundred nineteen available fundamental signals for Castle Biosciences, which can be analyzed over time and compared to other ratios. We recommend to validate Castle Biosciences' prevailing fundamental drivers against the all of the trends between 2010 and 2024.

Castle Biosciences Total Revenue

230.78 Million

Check Castle Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Castle Biosciences' main balance sheet or income statement drivers, such as Tax Provision of 125 K, Net Interest Income of 10.3 M or Interest Income of 10.3 M, as well as many indicators such as Price To Sales Ratio of 2.5, Dividend Yield of 0.0 or PTB Ratio of 1.55. Castle financial statements analysis is a perfect complement when working with Castle Biosciences Valuation or Volatility modules.
  
Check out the analysis of Castle Biosciences Correlation against competitors.
For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.

Castle Biosciences Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets311 M477.8 M157.2 M
Slightly volatile
Short and Long Term Debt Total14 M15.3 M17.1 M
Slightly volatile
Other Current Liabilities38.1 M36.3 M11.7 M
Slightly volatile
Total Current Liabilities24.6 M47.7 M14.5 M
Slightly volatile
Other Liabilities467.6 K492.2 K2.3 M
Pretty Stable
Property Plant And Equipment Net39.6 M37.7 M9.5 M
Slightly volatile
Current Deferred Revenue8 M7.6 M3.2 M
Slightly volatile
Accounts Payable10.8 M10.3 M2.8 M
Slightly volatile
Cash167.5 M98.8 M82.8 M
Slightly volatile
Non Current Assets Total191.3 M182.2 M45.3 M
Slightly volatile
Other Assets2.4 M2.5 M2 M
Slightly volatile
Long Term Debt22.5 M22.2 M19.1 M
Slightly volatile
Cash And Short Term Investments211.5 M243.1 M104.4 M
Slightly volatile
Net Receivables19.4 M38.3 M11.7 M
Slightly volatile
Common Stock Total Equity30.2 K28.8 K11.2 K
Slightly volatile
Common Stock Shares Outstanding19.8 M26.8 M14.3 M
Slightly volatile
Long Term Debt Total22.5 M22.2 M19.1 M
Slightly volatile
Liabilities And Stockholders Equity311 M477.8 M157.2 M
Slightly volatile
Non Current Liabilities Total22.6 M38.9 M19.9 M
Pretty Stable
Capital Surpluse165.8 M157.9 M58.7 M
Slightly volatile
Inventory8.3 M7.9 M1.9 M
Slightly volatile
Other Current Assets4 M6.3 M2.2 M
Slightly volatile
Other Stockholder Equity360.5 M609.5 M177.7 M
Slightly volatile
Total Liabilities47.2 M86.5 M34.4 M
Slightly volatile
Property Plant And Equipment Gross48.1 M45.9 M10.7 M
Slightly volatile
Total Current Assets237.7 M295.6 M119.8 M
Slightly volatile
Net Working Capital213.1 M248 M105.3 M
Slightly volatile
Intangible Assets68.5 M106.6 M37.2 M
Slightly volatile
Common Stock19.6 K31.1 K10.8 K
Slightly volatile
Property Plant Equipment32 M30.5 M8.6 M
Slightly volatile
Capital Stock23.1 K24.3 K27.9 M
Slightly volatile

Castle Biosciences Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income10.3 M9.8 M1.7 M
Slightly volatile
Depreciation And Amortization12.9 M12.3 M2.9 M
Slightly volatile
Interest Expense10.4 K11 K1.5 M
Slightly volatile
Selling General Administrative50.2 M66.5 M31.8 M
Slightly volatile
Total Revenue230.8 M219.8 M61.9 M
Slightly volatile
Gross Profit172.4 M164.2 M47 M
Slightly volatile
Other Operating Expenses302.2 M287.8 M86 M
Slightly volatile
Research Development56 M53.3 M16.3 M
Slightly volatile
Cost Of Revenue58.3 M55.6 M14.9 M
Slightly volatile
Total Operating Expenses243.8 M232.2 M71.1 M
Slightly volatile
Reconciled Depreciation12.5 M11.9 M2.8 M
Slightly volatile
Selling And Marketing Expenses110.1 M113.7 M90 M
Slightly volatile

Castle Biosciences Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation53.8 M51.2 M11.6 M
Slightly volatile
Begin Period Cash Flow152.7 M122.9 M77.4 M
Slightly volatile
Depreciation12.9 M12.3 M2.9 M
Slightly volatile
Capital Expenditures14.3 M13.6 M3.1 M
Slightly volatile
End Period Cash Flow167.5 M98.8 M82.8 M
Slightly volatile
Issuance Of Capital Stock180.7 M288.1 M97.3 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.52.631611.9219
Slightly volatile
Days Sales Outstanding10863.6078111
Slightly volatile
Average Payables1 M1.2 M1.3 M
Slightly volatile
Stock Based Compensation To Revenue0.240.2330.0801
Slightly volatile
Capex To Depreciation1.051.10471.9992
Very volatile
EV To Sales2.142.251511.7934
Slightly volatile
Inventory Turnover8.696.99511.8077
Slightly volatile
Days Of Inventory On Hand42.6252.180438.241
Slightly volatile
Payables Turnover4.05.41044.6558
Slightly volatile
Sales General And Administrative To Revenue0.290.30250.7891
Slightly volatile
Average Inventory661.2 K953.7 K746.3 K
Slightly volatile
Research And Ddevelopement To Revenue0.20.24250.2836
Slightly volatile
Capex To Revenue0.03220.0620.0377
Pretty Stable
Cash Per Share7.529.07024.9473
Slightly volatile
Days Payables Outstanding84.167.462679.9285
Slightly volatile
Intangibles To Total Assets0.260.24560.0932
Slightly volatile
Current Ratio6.946.20215.106
Slightly volatile
Receivables Turnover3.465.73833.6311
Slightly volatile
Graham Number27.8626.537912.5875
Slightly volatile
Capex Per Share0.530.50820.1456
Slightly volatile
Average Receivables10.7 M12 M13.1 M
Slightly volatile
Revenue Per Share8.618.20043.2367
Slightly volatile
Interest Debt Per Share0.540.57261.6411
Slightly volatile
Debt To Assets0.03050.03211.1057
Slightly volatile
Operating Cycle167116150
Very volatile
Days Of Payables Outstanding84.167.462679.9285
Slightly volatile
Ebt Per Ebit1.280.84391.1535
Very volatile
Long Term Debt To Capitalization0.03330.0352.9522
Slightly volatile
Total Debt To Capitalization0.03580.03772.4286
Slightly volatile
Quick Ratio6.856.03555.0238
Slightly volatile
Net Income Per E B T1.071.00180.9887
Pretty Stable
Cash Ratio1.972.07363.2875
Slightly volatile
Cash Conversion Cycle82.5848.325570.0476
Very volatile
Days Of Inventory Outstanding42.6252.180438.241
Slightly volatile
Days Of Sales Outstanding10863.6078111
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio10710214.7957
Slightly volatile
Fixed Asset Turnover5.535.82399.7246
Pretty Stable
Debt Ratio0.03050.03211.1057
Slightly volatile
Price Sales Ratio2.52.631611.9219
Slightly volatile
Asset Turnover0.630.460.9598
Slightly volatile
Gross Profit Margin0.620.74720.705
Slightly volatile

Castle Biosciences Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap182.3 M205.1 M223.4 M
Slightly volatile
Enterprise Value198.4 M223.1 M243 M
Slightly volatile

Castle Fundamental Market Drivers

Cash And Short Term Investments243.1 M

Castle Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Castle Biosciences Financial Statements

Castle Biosciences investors utilize fundamental indicators, such as revenue or net income, to predict how Castle Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue7.6 M8 M
Total Revenue219.8 M230.8 M
Cost Of Revenue55.6 M58.3 M
Stock Based Compensation To Revenue 0.23  0.24 
Sales General And Administrative To Revenue 0.30  0.29 
Research And Ddevelopement To Revenue 0.24  0.20 
Capex To Revenue 0.06  0.03 
Revenue Per Share 8.20  8.61 
Ebit Per Revenue(0.31)(0.32)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Castle Biosciences is a strong investment it is important to analyze Castle Biosciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Castle Biosciences' future performance. For an informed investment choice regarding Castle Stock, refer to the following important reports:
How To Invest In Castle
Details
Is Castle Stock a good investment?
Details
What is Castle Biosciences' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Castle Biosciences Correlation against competitors.
For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.
You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Castle Biosciences. If investors know Castle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Castle Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.93)
Earnings Share
(0.12)
Revenue Per Share
10.554
Quarterly Revenue Growth
0.735
Return On Assets
(0.02)
The market value of Castle Biosciences is measured differently than its book value, which is the value of Castle that is recorded on the company's balance sheet. Investors also form their own opinion of Castle Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Castle Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Castle Biosciences' market value can be influenced by many factors that don't directly affect Castle Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Castle Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Castle Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Castle Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY